To describe peri-operative results, functional outcomes and complications of laser photoselective vaporization, using the GreenLight system, of prostate glands ≥200 mL in volume.
Introduction
GreenLight laser photoselective vaporization of the prostate (PVP) has significantly evolved over the past decade and has rapidly gained widespread popularity for BPH treatment in North America and in Europe. According to European Association of Urology and AUA guidelines on the management of male non-neurogenic LUTS, PVP with GreenLight laser XPS is superior to TURP for prostates <80 mL in volume, with regard to intra-operative safety and postoperative complication rates such as bleeding [1, 2] .
For glands >80 mL other than open retropubic prostatectomy, holmium laser enucleation of the prostate (HoLEP) is the preferred treatment option [3] . Unfortunately, as a result of a difficult learning curve, the need for access to additional surgical materials, and the use of intravesical morcellation, penetration of the HoLEP approach within the urological community over the past two decades has been limited [4] .
A previous report has suggested that GreenLight PVP using the XPS 180W is safe and effective in treating patients with prostate volumes >100 mL even if it cannot be considered a size-independent procedure [5] . The experience and the data supporting the use of the GreenLight system for treating very large glands (>200 mL) is very limited [6, 7] . In the present study, we aimed to describe the peri-operative results as well as functional outcomes and complications of PVP for prostate glands >200 mL using the GreenLight system in a multiinstitutional cohort.
Materials and Methods

Patient Population
We conducted a multi-institutional, retrospective study of prospectively collected data for patients treated with GreenLight laser PVP for BPH using the XPS 180W system. Treatment indications were in accordance with the American, Canadian and European clinical practice guidelines. Surgeries were performed at four hospital centres in three different countries: Canada (University of Montreal Health Centre, University of Toronto), the USA (New York PresbyterianWeill Cornell Medical Centre) and France (Tours Hospital Centre) between the years 2007 and 2015. Only patients with a prostate volume >100 mL identified on preoperative TRUS were included in the study. A subgroup of patients with very large prostates was arbitrarily defined as those with glands ≥200 mL. Patients with a prostate cancer diagnosis were excluded from the analyses, and, patients with missing preoperative characteristics or substantial follow-up data were also excluded. Institutional review board approval was obtained.
Surgical Procedure
All patients underwent PVP performed as previously described using the XPS 180W system [8, 9] . The procedures were performed according to published International GreenLight use (IGLU) guidelines and incorporated the surgeon's own technique and experience. All procedures were performed under general or spinal anaesthesia. Preoperative antibiotic prophylaxis was administered to all patients according to local practice guidelines. All surgeons used the three lobes approach for PVP. In short, the vaporization procedure starts with the creation of a working space with 80 W power at 5 and 7 o'clock. The remainder of the prostate was vaporized in a circumferential manner with respect to the following anatomical landmarks: prostate capsule; bladder neck; and verumontanum. Vaporization was conducted using a maximum power of 180 W, adjustable in 10-20-W steps with the XPS system. For coagulation, the TruCoag feature pulse, modulated at 12 Hz and 5-40 W, was used. A 23-F continuous-flow cystoscope was used. MoXy fibres were used with the XPS system and irrigated with cooled or room temperature saline irrigation.
Variables
Preoperative variables were collected from patients' charts. Previous BPH medical and surgical history, including previous TURP, length of catheterization/retention and use of BPH medications (a-blocker and inhibitors of 5-a reductase), were captured. Prostate size was measured in all patients using TRUS. The presence of a median lobe was also recorded.
Preoperative symptoms index score (IPSS), uroflowmetry (maximum urinary flow rate [Q max ] and postvoid residual urine volume [PVR]) as well as PSA level (ng/mL) were included in the analysis and coded as continuous variables.
Finally, operative characteristics were also collected. This included total operating time, laser time, energy use (kJ), number of fibres and energy density delivery (kJ/cc). The latter was calculated by dividing energy use per prostate volume as measured by preoperative TRUS.
Outcomes
Patients were followed postoperatively at 6, 12, 24, 36 and up to 48 months. During follow-up visit, symptoms score (IPSS), uroflowmetry (Q max and PVR) values and PSA level were recorded.
Peri-operative and postoperative complications were also prospectively recorded. Peri-operative complications included complications that happened intra-operatively and during hospitalization: bleeding; capsular perforation; conversion to TURP; failure to remove catheter; and hospital stay. Postoperative complications included complications after hospital discharge. These were recorded between discharge and 6 months after surgery. All complications were graded according to the Clavien-Dindo classification system [10] . Finally, re-treatment rate was also evaluated at 12, 24 and 36 months after PVP surgery.
Statistical Analyses
Descriptive statistics focused on frequencies and proportions for categorical variables. Means, medians and interquartile ranges were reported for continuous variables. The Mann-Whitney test and chi-squared test were used to compare the statistical significance of differences in medians and proportions, respectively. All statistical tests were performed using an SPSS software environment for statistical computing and graphics (IBM Corp., version 20 Armonk, NY, USA). All tests were two-sided, with P values <0.05 taken to indicate statistical significance.
Results
Baseline Characteristics
Descriptive statistics of patients' demographics are shown in Table 1 . Overall, 88 patients with TRUS prostate volumes 874 © 2018 The Authors BJU International © 2018 BJU International ≥200 mL were treated with GreenLight 180W XPS PVP for BPH. The mean (interquartile range) overall follow-up was 16 (6-48) months. The median (interquartile range) prostate volume of the study group (prostate volume ≥200 mL) was 224 (207-261) mL and that of the control group (prostate volume 100-200 mL) was 150 (117-171) mL. The median age at surgery was 77 years for the study group vs 71 years in the control group. Regarding BPH history of patients in the control group (prostate volume <200 mL), 80% were on ablockers compared with 50% in the study group (prostate volume ≥200 mL; P = 0.004). The proportion of patients receiving 5a-reductase inhibitor treatment was higher in the study group than in the control group: 78% vs 47% (P = 0.05). Previous TURP was performed in 24% of patients regardless of prostate size. In the control group, 50% had an indwelling urinary catheter at the time of surgery compared with 44% of the study group. IPSS, Q max , PVR, body mass index and the presence of a median lobe were characteristics that did not differ between the groups.
Peri-operative characteristics are described in Table 2 . The median operating time was 126 min with a median total energy of 656 kJ for the study group (prostate volume ≥200 mL) vs 82 min with 440 kJ for the control group (P < 0.01 for both). Moreover, the number of fibres used was also significantly different between the groups: 3 vs 2 fibres in the study group vs the control group (P < 0.01). The median energy density was 2.81 kJ/mL in the study group vs 3.03 kJ/mL in the control group (P = 0.31). Significantly more conversions to TURP were found in the study group (16% vs 4%; P = 0.04). Hospital stay did not differ between the groups (Table 2) .
At all follow-up endpoints, a similar decrease in PSA levels was observed for both groups. Q max , IPSS and quality of life score were significantly improved after surgery at all endpoints compared with baseline and in a statistically similar manner in the two groups (Table 3) .
Safety
Overall complications were similar in the study group vs the control group (37% vs 34%; P = 0.7). Peri-operative complications did not differ 3% vs 4% (P = 0.9), but there were more conversions to TURP as a result of bleeding in the study group (prostate volume ≥200 mL), as previously stated. There were no differences in postoperative complications distribution according to Clavien-Dindo classification. No Clavien grade ≥4 complications were reported (Table 4) .
Re-treatment
The re-treatment rate was 6% for the study group (prostate volume ≥200 mL) vs 9% for the control group (prostate volume 100-200 mL) at a mean follow-up of 15.9 months (P = 0.61) ( Table 4) .
Discussion
To the best of our knowledge, there are no documented size limits when planning a GreenLight PVP procedure for BPH. There is evidence in the literature that GreenLight PVP using the XPS 180W system is both safe and feasible, yielding durable functional improvements in experienced hands. As previously shown, GreenLight PVP of prostate glands ≥100 mL in volume is both a safe and durable procedure when using >3-4 kJ/mL of prostate, although it is associated with higher retreatment rates [5, 11] . The objective of the present study was to determine the feasibility, safety and durability of GreenLight PVP in patients with very large glands (≥200 mL). The threshold of 200 mL was chosen from consensus among surgeons who considered it a challenging size but not too rare to have enough cases for analysis.
Very large glands (≥200 mL) were associated with longer operating times (126 vs 82 min) and a greater number of fibres used per case (3 vs 2 fibres). Moreover, very large glands were more prone to TURP conversion as a result of bleeding intra-operatively (16% vs 4%). Previous reports have shown bleeding-related conversion to TURP rates in the order of 16%, depending on the prostate size [7, 12] . Furthermore, in a recent study, Meskawi et al. [5] reported a low rate of TURP conversion of 6% in glands >100 mL. These peri-operative results highlight the most important differences when treating very large glands: time and hospital resources. Although cost-effectiveness was not analysed, it can be inferred that the number of fibres used and the operating time significantly drives cost and will proably compare unfavourably with an enucleation technique (GreenLEP or HoLEP).
Despite the peri-operative differences, we did not find any differences in functional results at 48 months of follow-up. PSA level reduction, Q max , quality-of-life score and IPSS were found to be statistically similar in the two groups. This highlights the persistence of functional improvement after GreenLight PVP for glands as big as ≥200 mL. Even though we did not study the learning curve effect, nor account for the experience of each surgeon, it must be noted that all surgeons included in the present study were experts in the field and were beyond their learning curve. Currently, there is no consensus on the number of cases for the learning curve of GreenLight XPS, but it is agreed that the number of procedures will have an impact on surgical results. In a recent multicentre study, the number of procedures performed (≥100) was an important predictor of favourable outcomes [13] .
Complication rates as per Clavien-Dindo classification at a mean (range) follow-up of 16 (0-48) months did not differ between the groups. Moreover, we did not find higher BPHrelated retreatment rates in the study (very large prostate) group when compared with the control group (6% vs 9%).
Either the follow-up time was not long enough or the number of cases of very large glands (n = 33) was too low to yield statistical significance. Clearly an update in follow-up is warranted because regrowth of adenoma can occur up to 10 years later.
Previous reports have suggested that the amount of tissue removed during PVP is significantly smaller than that removed during HoLEP [14] . Objective measurements of prostate volume change were not performed in the present study; however, serum PSA decline and nadir was statistically different in the retreated patient. This difference in PSA decrease probably reflects the smaller amount of adenoma removed and that underlies the risk of a higher rate of treatment failure in the long term. A PSA decrease of a minimum of 50% should be observed at 6 months as previously reported for durable outcomes [15, 16] . In the present study, the PSA decrease at 6 months in the study group (prostate volume ≥200 mL) did not reach this minimum (46%) and was significantly lower than the control group (prostate volume <200 mL) at 2 years.
Surgical procedures for very large adenoma remain limited. Open prostatectomy and HoLEP are the procedures of choice according to guidelines. Recently, robot-assisted simple prostatectomy has emerged as an alternative to open simple prostatectomy, with reduced bleeding and length of hospitalization [17] . Two recent studies have compared HoLEP and robot-assisted simple prostatecomy [18, 19] . Although these two techniques are equally effective, hospitalization stay and duration of catheterization seem to favour HoLEP. Alternatively, enucleation can be achieved using other energy sources such as GreenLight, thulium or bipolar. Nevertheless, it remains uncertain whether this will translate into widespread adoption of these techniques. For the time being, a GreenLight vapo-enucleation technique performed by an experienced surgeon remains a fair alternative for treating large glands without the need for morcellation [6] .
Limitations of the present study include its retrospective nature and loss to follow-up. Heterogeneity between centres in terms of surgeons' techniques, and assiduity of follow-up are an inherent bias but may also be reflective of real clinical practice. The nature of the comparison could be viewed as a limitation (≥200 mL vs 100-200 mL), but we considered that comparing results for small glands <80 mL with those for very large glands would yield obvious results. When Table 4 Overall complication and retreatment rates in 88 patients treated with XPS GreenLight GreenLight laser photoselective vaporization of the prostaten stratified according to prostate volume.
Complication and re-treatment rates 100-200 mL (n = 55) >200 mL (n = 33) comparing large glands with 'very large' glands, the results should help determine a size limit for such a procedure. Also of importance is the performance of PVP by high-volume, expert surgeons who have overcome the learning curve for procedure proficiency [20] . As such, the results should take into account the surgeon skill set and may not be transferable to surgeons with low volume and experience.
In conclusion, in experienced hands, PVP GreenLight XPS 180W is a safe and feasible technique for very large prostates (≥200 mL) when compared with large prostates (100-200 mL). Complications, re-treatment rates and functional outcomes in patients with prostates ≥200 mL were similar to those in patients with prostates 100-200 mL in volume. These results can be used for patient counselling and surgery planning. Operating times, number of fibres used and conversion to TURP, however, are of concern.
